Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-70P is a pseudogene derived from the sequence of U6 small nuclear RNA, a core component of the spliceosome responsible for pre-mRNA splicing in eukaryotic cells[1][3]. While the canonical U6 snRNA is essential for catalysis within the spliceosome and exhibits diverse post-transcriptional modifications[1], pseudogenes like RNU6-70P are formed by retrotransposition and do not encode functional RNAs or proteins[3]. Pseudogenes can be used to study retrotransposition and genome evolution, but do not have direct biological or therapeutic functions. Thus, RNU6-70P is not considered a functional or pharmacologic target[3]. If you require information about functional U6 small nuclear RNA, it is a critical RNA molecule in RNA splicing and is not a receptor, enzyme, or druggable target, but rather a catalytic RNA element of the spliceosome[1]. RNU6-70P, however, is just a non-functional genomic remnant with no evidence of medical targeting or drug interaction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 70 pseudogene (RNU6-70P).